Researchers at the University of Queensland have been awarded funding to advance work across mRNA research, cancer vaccines and single-cell genomic technologies.

Patrys Ltd. has announced new preclinical data for its full-sized IgG antibody, PAT-DX3.

Biomea Fusion Inc. has received IND clearance from the FDA to begin a phase I/Ib trial of BMF-219, a selective, covalent menin inhibitor in patients with unresectable, locally advanced, or metastatic non-small-cell lung cancer (NSCLC), colorectal cancer, or pancreatic ductal adenocarcinoma with an activating KRAS mutation.

Increasing evidence exists regarding estrogen receptor β (ERβ) playing a protective role in Alzheimer’s disease (AD) and its loss resulting in progressive neural cell body degeneration.

Akeso Inc. has received approval from China's National Medical Products Administration (NMPA) for a phase Ib/II trial of ivonescimab (AK-112) combined with drebuxelimab (AK-119) for the treatment of advanced solid tumors.

Researchers from Meiragtx Ltd. presented preclinical data on a new and optimized gene therapy based on a mini ATP7B gene for the potential treatment of Wilson’s disease (WD), a rare (1:30,000) autosomal recessive genetic disease caused by loss-of-function mutations in ATP7B, leading to a pathologically high amount of copper in the liver and brain.

Additional early-stage research and drug discovery news in brief, from: Derm-Biome, Editas.